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Proteomic analysis of the S. cerevisiae response
to the anticancer ruthenium complex KP1019
Laura K. Stultz,a Alexandra Hunsucker,b Sydney Middleton,a Evan Grovenstein,b
Jacob O’Leary,a Eliot Blatt,c Mary Miller,c James Mobleyd and
Pamela K. Hanson *e
Like platinum-based chemotherapeutics, the anticancer ruthenium complex indazolium trans-[tetra-
chlorobis(1H-indazole)ruthenate(III)], or KP1019, damages DNA, induces apoptosis, and causes tumor
regression in animal models. Unlike platinum-based drugs, KP1019 showed no dose-limiting toxicity in a
phase I clinical trial. Despite these advances, the mechanism(s) and target(s) of KP1019 remain unclear.
For example, the drug may damage DNA directly or by causing oxidative stress. Likewise, KP1019 binds
cytosolic proteins, suggesting DNA is not the sole target. Here we use the budding yeast Saccharomyces
cerevisiae as a model in a proteomic study of the cellular response to KP1019. Mapping protein level
changes onto metabolic pathways revealed patterns consistent with elevated synthesis and/or cycling of
the antioxidant glutathione, suggesting KP1019 induces oxidative stress. This result was supported by
increased fluorescence of the redox-sensitive dye DCFH-DA and increased KP1019 sensitivity of yeast
lacking Yap1, a master regulator of the oxidative stress response. In addition to oxidative and DNA stress,
bioinformatic analysis revealed drug-dependent increases in proteins involved ribosome biogenesis,
translation, and protein (re)folding. Consistent with proteotoxic effects, KP1019 increased expression of a
heat-shock element (HSE) lacZ reporter. KP1019 pre-treatment also sensitized yeast to oxaliplatin,
paralleling prior research showing that cancer cell lines with elevated levels of translation machinery are
hypersensitive to oxaliplatin. Combined, these data suggest that one of KP1019’s many targets may be
protein metabolism, which opens up intriguing possibilities for combination therapy.
Significance to metallomics
The ruthenium complex KP1019 has promising anticancer properties, yet its mechanisms of action are only partially understood. Using budding yeast as a
model system, here we report the first global proteomic analysis examining the cellular response to this drug. One of the strongest signatures revealed by this
work was elevated levels of proteins involved in ribosomal biogenesis (ribi) and translation, suggesting that KP1019 perturbs protein homeostasis. Previous
studies showed that enhanced ribi gene expression is associated with increased sensitivity to oxaliplatin. Our observation of synergy between KP1019 and
oxaliplatin suggests future promise for combination therapy.
Introduction
Certain metals, including iron and copper, serve essential
functions in cells. However, at high levels, many metals are toxic.
Although mechanisms of toxicity can vary, leading to divergent
cellular responses,1,2 many metals have been shown to induce
oxidative stress and DNA damage.3–6 Some metals have also been
shown to induce protein misfolding and aggregation.7
In recent decades, the toxicity of a diverse array of metals has
been harnessed in the production of anti-cancer drugs.8–11 Early
examples include cisplatin and carboplatin, which are often used
to treat testicular and ovarian cancers, as well as head and neck
tumours. More recently, oxaliplatin has emerged as an effective
treatment for gastrointestinal cancers,12,13 and it may be particu-
larly effective in the context of combination therapies.14 Unfortu-
nately, the utility of platinum-based drugs can be hindered by
dose-limiting toxicity and development of drug resistance.15–17
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Though not yet approved for regular use, three ruthenium
complexes – NAMI-A, KP1019, and KP1339 – show significant
promise in preclinical studies and early clinical trials.18,19
For example, indazolium trans-[tetrachlorobis(1H-indazole)
ruthenate(III)], or KP1019 (Fig. 1), displays no dose-limiting
toxicity20,21 and maintains potency against drug resistant cell
lines.22 KP1019 caused tumour regression in animal models,23
and in a phase I clinical trial, the drug stabilized disease
progression in five of six evaluable patients.20,21 However, this
drug’s mechanism of action remains poorly understood. In
colorectal cancer cells, KP1019 has been shown to induce
oxidative stress and DNA damage,24 yet in cervical carcinoma
cells, the drug bound primarily to proteins in the cytosolic
fraction.25 Furthermore, KP1019 not only bound genomic DNA
but also accumulated in mitochondria of ovarian cancer cells.26
Consistent with findings in cancer cell lines, KP1019 has
been shown to inhibit growth, induce cell death, and damage
DNA in the budding yeast Saccharomyces cerevisiae.27–29 More-
over, the drug bound readily with cytoplasmic proteins and
mitochondria of fractionated yeast cells.30 KP1019’s ability to
induce stress is also consistent with its ability to activate the
evolutionarily conserved stress-responsive kinase Hog131 and to
increase lipid droplet formation.32 Combined, these studies
suggest that KP1019 has multiple modes of action in yeast,
much like it has in cultured mammalian cells. Thus, budding
yeast appears to be an appropriate model organism for better
characterizing KP1019’s impact on cells.
When working with poorly characterized drugs, unbiased
genome-wide approaches can help establish the targets of
bioactive compounds.33,34 For example, transcriptional profiling
of yeast helped uncover quinine’s ability to perturb glucose
transport35 and contributed to establishment of calcium mobility
as a mechanism of action for the antifungal terpenoid phenol
carvacrol.36
Given the success of such global approaches, we have used
mass spectrometry to analyse the effects of KP1019 on the budding
yeast proteome. Our results support previous findings, verifying
activation of the DNA damage response, while revealing new
physiological responses to the drug, such as morphogenesis,
metabolic re-tooling, and induction of ribosomal biogenesis.
Materials and methods
Yeast strains and growth conditions
Yeast strains used in this study are listed in Table 1. Yeast were
grown under standard conditions, at 30 1C using the rich
medium yeast extract peptone dextrose (YPD) (1% yeast extract,
2% bacto-peptone, 2% dextrose) or synthetic complete media
(SDC) as indicated.39 For experiments involving plasmids, a
standard lithium acetate transformation protocol40 was used,
and transformants were selected on minimal media lacking the
component necessary for plasmid maintenance.
Drug synthesis
KP1019 was synthesized using a protocol described previously27
and adapted from Lipponer et al.41 Briefly, 1 g RuCl3  3H2O
was added to 20 ml of 12 M HCl and 20 ml of ethanol and
refluxed for 1 hour. Once the reaction mixture had cooled, the
ethanol was removed using a rotary evaporator, and 12 M HCl
was added to give a final volume of 40 ml. The ruthenium
solution was combined with 3.74 g of indazole that had been
dissolved in 60 ml of 12 M HCl at 70 1C. This reaction mixture
was heated for 15 minutes at 80–90 1C and cooled to room
temperature with stirring. The resulting solid was filtered from
the solution, and then stirred in approximately 150 ml of H2O
at room temperature for 2 hours. The solid was filtered and
subsequently washed with cold ethanol followed by cold diethyl
ether. The drug was dried under vacuum for 18–24 hours.
KP1019 purity was verified by UV-visible spectroscopy, elemental
analysis and cyclic voltammetry.
Proteomic analysis
Proteomic analysis was carried out as previously,42 with minor
changes included below.
Sample preparation. For each of three biological replicates,
250 ml of wild-type yeast (BY 4742) were grown to mid-log phase
Fig. 1 Structure of KP1019 (indazolium trans-[tetrachlorobis(1H-
indazole)ruthenate(III)]).
Table 1 Yeast strains used in this study
Strain Genotype Ref.
BY 4742 MATa his3D1 leu2D0 lys2D0 ura3D0 Winzeler et al., 199937
yap1D yap1::kanMX In BY4742 Winzeler et al., 199937
dun1D dun1::kanMX In BY4742 Winzeler et al., 199937
ddc1D ddc1::kanMX In BY4742 Winzeler et al., 199937
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(OD600 0.5–1.0) at 30 1C in SDC. The culture was then split and
half was treated with 80 mg ml1 KP1019 for 3 hours; the other
half was left untreated. Samples were washed with water and
cell concentrations were normalized. Cells were then pelleted
and stored at 80 1C. The Y-PER Yeast Protein Extraction
Reagent (Thermo Fisher, Waltham, MA) was used to extract
proteins from the pellets. The protein fractions were quantified
using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific,
Cat.# PI23225), B20 mg of protein per sample were then diluted
to 35 ml using NuPAGE LDS sample buffer (1 final conc.,
Invitrogen, Cat.#NP0007). Proteins were then reduced with DTT
and denatured at 70 1C for 10 min prior to loading everything
onto Novex NuPAGE 10% Bis–Tris protein gels (Invitrogen,
Cat.# NP0315BOX) and separated as a short stack (10 min
at 200 constant V). The gels were stained overnight with
Novex Colloidal Blue Staining kit (Invitrogen, Cat.# LC6025).
Following de-staining, each lane was cut into single MW
fractions and equilibrated in 100 mM ammonium bicarbonate
(AmBc), each gel plug was then digested overnight with Trypsin
Gold, Mass Spectrometry Grade (Promega, Cat.# V5280) following
manufacturer’s instruction. Peptide extracts were reconstituted in
0.1% formic acid/ddH2O at 0.1 mg ml
1.
Mass spectrometry. Peptide digests (8 mL each) were injected
onto a 1260 Infinity nHPLC stack (Agilent Technologies), and
separated using a 75 micron I.D.  15 cm pulled tip C-18
column (Jupiter C-18 300 Å, 5 micron, Phenomenex). This
system runs in-line with a Thermo Orbitrap Velos Pro hybrid
mass spectrometer, equipped with a nano-electrospray source
(Thermo Fisher Scientific), and all data were collected in CID
mode. The nHPLC was configured with binary mobile phases
that included solvent A (0.1% FA in ddH2O), and solvent B
(0.1% FA in 15% ddH2O/85% ACN), programmed as follows;
10 min @ 5%B (2 ml min1, load), 90 min @ 5–40% B (linear:
0.5 nl min1, analyse), 5 min @ 70% B (2 ml min1, wash),
10 min @ 0% B (2 ml min1, equilibrate). Following each parent
ion scan (300–1200 m/z @ 60k resolution), fragmentation data
(MS2) was collected on the top most intense 15 ions. For data
dependent scans, charge state screening and dynamic exclu-
sion were enabled with a repeat count of 2, repeat duration of
30 s, and exclusion duration of 90 s.
MS data conversion and searches. The XCalibur RAW files
were collected in profile mode, centroided and converted to
MzXML using ReAdW v. 3.5.1. The mgf files were then be
created using MzXML2Search (included in TPP v. 3.5) for all
scans. The data was searched using SEQUEST, which was set for
two maximum missed cleavages, a precursor mass window of
20 ppm, trypsin digestion, variable modification C @ 57.0293,
and M @ 15.9949. Searches were performed with a species
specific subset of the UniRef100 database.
Peptide filtering, grouping, and quantification. The list of
peptide IDs generated based on SEQUEST (Thermo Fisher
Scientific) search results were filtered using Scaffold (Protein
Sciences, Portland Oregon). Scaffold filters and groups all
peptides to generate and retain only high confidence IDs while
also generating normalized spectral counts (N-SC’s) across all
samples for the purpose of relative quantification. The filter
cut-off values were set with minimum peptide length of
45 AA’s, with no MH + 1 charge states, with peptide probabilities
of 480% C.I., and with the number of peptides per protein Z2.
The protein probabilities were then set to a 499.0% C.I., and an
FDR o 1.0. Scaffold incorporates the two most common methods
for statistical validation of large proteome datasets, the false
discovery rate (FDR) and protein probability.43–45 Relative quanti-
fication across experiments were then performed via spectral
counting,46,47 and when relevant, spectral count abundances were
then normalized between samples.48
Systems analysis. Gene ontology assignments, clustering,
and pathway analysis were carried out using Search Tool for
Recurring Instances of Neighbouring Genes (STRING; https://
string-db.org/),49 Protein ANalysis THrough Evolutionary
Relationships (PANTHER; http://www.pantherdb.org/),50 and
YeastMine (http://yeastmine.yeastgenome.org).51
Filamentation assay
A wild-type strain from the filamentation competent S1278b
background52,53 was cultured overnight in SDC then spread
onto SDC media containing the indicated concentrations of
KP1019. After an 18 hour incubation at 30 1C colony morphology
was documented using a Zeiss Axioskop 2 plus with Zeiss
Axiovision software (Carl Zeiss AG, Oberkochen, Germany).
Oxidative stress assay
Wild-type yeast were cultured to mid-log phase then incu-
bated with 50 mM 20,70-dichlorodihydrofluorescein diacetate
(DCFH-DA; Sigma-Aldrich, St. Louis, MO) for 1.5 hours at
30 1C to pre-load the cells with the redox sensitive dye. The
samples were then treated with 0 or 80 mg ml1 KP1019 or
10 mM H2O2 for 2.5 hours. Samples were then analysed by
flow cytometry using a BD Accuri C6 Flow Cytometer (Becton
Dickson, Franklin Lakes, NJ). 10 000 events were collected for
each sample.
Beta-galactosidase assays
The genotoxicity and proteotoxicity of KP1019 were verified
using wild-type yeast strain BY4742 transformed with the pZZ2
RNR3-lacZ or HSE-lacZ reporter constructs, respectively.54,55
Specifically, transformed cells were cultured to mid-log phase
(OD600 0.5–1.0) in selective media then treated with KP1019
dissolved in the same type of medium. Samples were incubated
for 3 hours to allow for gene induction, at which point
b-galactosidase activity was measured using the permeabilized
cell assay described by Guarente.56
Heat shock assay
The heat shock sensitivity assay was adapted from Wang et al.57
Briefly, yeast were cultured to mid-log phase at 30 1C in SDC
then treated with the indicated concentration of KP1019 for
2 hours. Cells were then washed with SDC and cell concentra-
tions were normalized. Samples were then incubated at 52 1C,
and aliquots were removed and pipetted onto YPD at the
indicated times. Following a 48 hour incubation at 30 1C,
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Drug sensitivity and synergy assays
Drug-containing SDC was subjected to 2-fold serial dilution
across the wells of a microtitre plate. Overnight cultures of yeast
were diluted to OD600 0.1 and subsequently diluted 20-fold
more in SDC. An equal volume of diluted cell suspension was
added to each well of the microtitre plate. After an 18 to 24 hour
incubation at 30 1C, the growth of each strain at each concen-
tration of drug was recorded as absorbance at 630 nm using a
BioTek (Winooski, VT) microtitre plate reader. Data were fit
with a sigmoidal 4-parameter logistic curve to determine the
concentration of drug that inhibited growth by 50%.
For the synergy assay, overnight cultures of yeast were sub-
cultured to mid-log phase (OD600 0.5–1.0) in SDC prior to
transferring the cells to SDC containing the indicated concen-
trations of KP1019. Following a three-hour incubation with the
drug, cells were harvested by centrifugation then resuspended
in drug-free SDC. Samples were then normalized to OD600 0.1
and subsequently diluted 10-fold more in SDC. One part yeast
suspension was then added to three parts oxaliplatin in SDC
to achieve the desired final concentration of platinum drug.
After an 18 to 24 hour incubation at 30 1C, yeast growth at each
concentration of drug was recorded as described above. The
resulting data were analysed using SynergyFinder.58
Results
Analysis of KP1019-dependent changes in protein abundance
To characterize the cellular response to the anticancer
ruthenium complex KP1019, we used a proteomic approach
to measure changes in protein abundance in yeast treated with
80 mg ml1 KP1019, a concentration used in a prior transcrip-
tomic study29 and previously shown to robustly inhibit yeast
growth and arrest the cell cycle while causing only modest
amounts of cell death.27 The yeast proteome was analysed after
incubating the cells with KP1019 for 3 hours,59 the same
duration of exposure used in prior transcriptomic studies of
this drug.29,32 Ultimately, 3676 different proteins were detected
across three biological replicates. To determine which proteins
displayed a significant change in expression level, a student’s
t-test was performed and proteins with p-values less than 0.05
were considered to display statistically significant differences in
abundance. In an attempt to enrich for physiologically significant
changes in protein levels, we limited further analysis to proteins
with a 1.5-fold or greater increase in abundance or a 25% or
greater decrease in abundance, consistent with a prior study
of stress-dependent changes in protein levels in yeast.60 Using
these criteria, levels of 230 proteins increased and 200 proteins
decreased following a three-hour incubation with the drug (Fig. 2).
Amongst these 430 proteins, fold change ranged from a high of
19-fold induction for the heat shock protein Hsp104, which
disaggregates proteins misfolded during stress,61,62 to a low of
24-fold repression for the spore wall protein Irc18.
To visualize networks of proteins impacted by KP1019,
STRING was used to map each set of proteins (induced vs. repressed)
onto the yeast interactome (Fig. 3A and 4A). Within STRING, clusters
of proteins were identified using the MCL algorithm set to an
inflation of 2.5, as a means of better separating clusters with
distinct functions. The networks of increased and reduced
abundance proteins both had significantly more interactions
than expected with protein–protein interaction (PPI) enrich-
ment p-values of 2  106 and 4  105, respectively. However,
the proteins of increased abundance tended to be grouped into
larger clusters containing up to 18 proteins (Fig. 3A), whereas
the largest cluster identified for proteins with reduced abun-
dance contained only 6 proteins (Fig. 4A). Network visualization
and analysis in STRING was paired with statistical analysis by
PANTHER, which identified and hierarchically organized bio-
logical process gene ontology (GO) terms that were significantly
(FDR o 0.05) enriched among the proteins with increased and
reduced abundance (Fig. 3B and 4B, respectively).
To identify transcription factors that may contribute to
KP1019-dependent changes in protein levels, the pool of
induced and repressed proteins were analysed in Yeastract
(http://www.yeastract.com).63 Specifically, we applied Yeas-
tract’s TFRank functionality with a heat diffusion coefficient
of 0.25 to avoid focusing on overly proximal or distal layers of
regulation.64 Implicated transcription factors are presented in
Fig. 5A. Since four of the top ten weighted transcription factors
Fig. 2 Volcano plot of proteomic data. Statistical significance was deter-
mined by a t-test across three biological replicates. Filled red circles
correspond to proteins with statistically significant (p o 0.05) and
Z1.5 fold increases in abundance following a 3 hour treatment with the
anticancer ruthenium complex KP1019. Filled blue circles correspond to
proteins with statistically significant (p o 0.05) and Z25% decreases in
abundance. Open grey symbols correspond to proteins that did not meet
these thresholds. Twenty-seven proteins were not detected in any of the
no drug replicates but were detected in all of the drug trials; these proteins
are not depicted in the volcano plot, due to this ‘‘infinite’’ fold change.
However, these proteins were included in subsequent bioinformatics
analyses. Similarly, 21 significantly (p o 0.05) repressed proteins that were
not detected in any of the drug trials were included in bioinformatics
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are known for their roles in filamentous growth and/or mor-
phogenesis, we conducted a preliminary validation of the
TFRank analysis by plating the filamentation competent strain
P
1278b52,53 on media containing varying concentrations of
KP1019. As seen in Fig. 5B, the drug induced a dose-dependent
increase in morphogenesis.
As will be discussed in more detail below, many of the
findings generated through bioinformatics analyses revealed
Fig. 3 Functional analysis of proteins with elevated levels following KP1019 treatment. (A) STRING was used to map proteins of increased abundance
onto the yeast interactome, using only known and predicted interactions with the highest confidence score (0.9). Nodes represent proteins of increased
abundance only, and edges represent confidence. Associations between clusters are indicated with dashed edges. Clusters were established via the MCL
algorithm with an inflation parameter of 2.5 to allow identification of a moderate number of clusters. Weak links and disconnected nodes are hidden for
clarity, as are clusters with fewer than four nodes. Graphs represent the log of the false discovery rate (FDR) for (B) the Biological Process GO terms at
the highest hierarchical level identified by PANTHER and (C) the KEGG Pathway Enrichment as determined by STRING. Dashed lines indicate the cut-off
for statistical significance (FDR = 0.05; log(FDR) = 1.3).
Fig. 4 Functional analysis of proteins with reduced levels following KP1019 treatment. (A) STRING was used to map proteins of decreased abundance
onto the yeast interactome as described for Fig. 3, except all clusters with three or more nodes are shown. (B) The Biological Process GO terms identified
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consistent themes, including activation of multiple stress
response pathways. In fact, one of the largest clusters identified
by STRING contains proteins involved in diverse biological
processes including cellular detoxification (e.g. – Sfa165), RNA
metabolism (e.g. – Rtc366), and signal transduction (e.g. – Tfs167)
(Fig. 3A). Though seemingly dissimilar, most have been shown to
be stress-responsive, increasing in abundance and/or changing
localization following application of environmental stressors.
For example, the glycogen branching enzyme Glc3, was pre-
viously shown to increase in abundance and form cytoplasmic
puncta upon induction of DNA replication stress.68
KP1019 activates oxidative stress responses
Given that KP1019 has previously been shown to induce oxidative
stress in colorectal carcinoma cells,24 it was not surprising to find
‘‘oxidation–reduction process’’ and ‘‘glutathione metabolism’’
amongst the enriched GO terms and Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathways, respectively (Fig. 3). Consistent
with these findings, bioinformatics analyses uncovered additional
evidence of metabolic retooling. For example, when proteins
displaying drug-dependent reductions in abundance were
analysed by STRING, ‘‘metabolic pathways’’ was identified as a
significantly enriched KEGG pathway (FDR = 0.0001). Likewise,
PANTHER revealed enrichment of proteins involved in purine
nucleotide and alpha amino acid metabolism (Fig. 4B).
To better integrate these bioinformatics findings, metabolic
enzymes displaying drug-dependent changes in abundance were
mapped onto several intertwined metabolic pathways (Fig. 6A).
This visualization reveals how these metabolic changes may
coordinately regulate increased synthesis and/or cycling of
the cellular antioxidant glutathione. In addition to increasing
abundance of enzymes (Gsh2, Gtt1, and Glr1) directly involved in
glutathione synthesis/cycling,69–71 KP1019 treatment increased
levels of several enzymes in the pentose phosphate pathway
(PPP), including the glucose-6-phosphate dehydrogenase Zwf1,
which catalyses the pathway’s rate-limiting step.72 Moreover,
drug exposure lowered levels of proteins involved in inositol
synthesis, potentially reducing the shunting of glucose-6-
phosphate out of the PPP. Increased flux through the PPP could
increase levels of NADPH,73 which is critical for glutathione
regeneration.74,75 Furthermore, YeastMine uncovered significant
changes to the S-adenosylmethionine (SAM) cycle (Benjamini–
Hochberg corrected p-value = 0.002), which can be visualized
as a cluster in Fig. 4A. This drug-dependent down-regulation
might also contribute to antioxidant synthesis by increasing the
proportion of de novo homocysteine available for conversion to
cysteine and incorporation into GSH.
To more directly measure KP1019’s ability to induce oxida-
tive stress, we used the redox sensitive fluorophore DCFH-DA.76
As seen in Fig. 6B, KP1019 treated cells displayed elevated levels
of fluorescence, consistent with drug-induced oxidative stress,
albeit significantly weaker than the hydrogen peroxide positive
control.
To gather independent confirmation of oxidative stress, we
leveraged the results of the TFRank analysis, which implicated
Yap1 (Fig. 5A), a major regulator of the yeast oxidative stress
response and the yeast orthologue of the human transcription
factor AP-1.75,77 Specifically, we examined the KP1019 sensitivity
of yeast lacking YAP1. As seen in Fig. 6C, we confirmed that
yap1D yeast are extremely sensitive to H2O2. Loss of YAP1
also caused a modest but statistically significant increase in
sensitivity to KP1019, a result consistent with the modest induc-
tion of DCFH-DA fluorescence noted previously.
KP1019 induces the DNA damage response
Since several studies have shown that KP1019 damages DNA, it
was surprising that the DNA damage response (DDR) was not
among the enriched biological process GO terms. However, the
Fig. 5 KP1019 induces morphogenesis in yeast. (A) All proteins with significant (p o 0.05) changes in abundance were analysed by the TFRank algorithm
in Yeastract. Graph depicts scores for the ten most strongly implicated transcription factors. (B) Colony morphology of filamentation competent S1278b
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ribonucleoside-diphosphate reductase (RNR) complex is visible
in the STRING clustering (Fig. 3A), and it was one of the few
specific cellular component GO terms that was significantly
enriched (FDR = 0.01) for the list of proteins with increased
abundance following KP1019 treatment. The RNR genes are
well established as downstream effectors in the yeast DDR.78,79
To verify that elevated RNR levels in KP1019 treated cells was
due to activation of the DDR, we examined expression of an
RNR3-lacZ reporter construct in yeast lacking DDC1 and DUN1,
which encode key mediators of the DDR.80–82 As can be seen in
Fig. 7A, KP1019-dependent induction of this reporter for
genotoxicity83 was blocked by disruption of the DDR. Consistent
with previous studies,28,29 activation of the DDR appears to be
physiologically significant, as deletion of DDC1 and DUN1
increases sensitivity to KP1019, decreasing the concentration of
drug that inhibits growth by 50% (IC50) from 6.8 (wild-type) to
3.6 and 3.0 mg ml1 for dun1D and ddc1D, respectively (Fig. 7B).
KP1019 affects protein synthesis and folding
Among the most consistent themes that emerged from analysis
of the proteomic data were protein (re)folding and protein
synthesis. As can be seen in Fig. 3, KP1019 elevated the levels
of chaperones that assist with protein (re)folding. Interestingly,
subjecting the induced protein dataset to publication enrich-
ment analysis in YeastMine revealed a potential connection to
the heat shock response. Specifically, three of the top 5 hits
(Benjamini Hochberg corrected p-values o0.0001) were
published articles focused on the heat shock response.
In yeast, the heat shock response (HSR) involves elevated
expression of chaperones. Consistent with activation of the
HSR, we observed KP1019-dependent increases in the abun-
dance of several heat shock proteins, including the HSP70
family members Ssa1-4 and the yeast HSP90 chaperones
Hsp82 and Hsc82 (Fig. 3A). To determine whether the HSR
transcriptional response might account for the changes in
chaperone levels observed in our data, we monitored expres-
sion of a lacZ reporter under control of a heat shock element
(HSE).84 Consistent with activation of the HSR, we observed a
small but statistically significant drug-dependent increase in
HSE-lacZ expression (Fig. 8A). Although a dose–response curve
indicated that 80 mg ml1 KP1019 (134 mM) results in maximal
activation of this reporter construct (data not shown),
the ability of 80 mg ml1 KP1019 to induce expression was
significantly lower than that of 100 mM cadmium (Fig. 8A).
Fig. 6 KP1019 induces oxidative stress resulting in metabolic retooling. (A) Changes in protein abundance are represented in the context of interacting
metabolic pathways. Blue text corresponds to metabolic intermediates. (B) Yeast were pre-loaded with the redox sensitive dye DCFH-DA prior to
treatment with KP1019 or hydrogen peroxide for 2.5 hours. Flow cytometry was used to measure the average fluorescence of 10 000 cells per condition
per trial. (C) Drug sensitivity assays were conducted as described in Materials and Methods. The resulting IC50 values were used to calculate relative
resistance by dividing each strain’s IC50 by the IC50 of the corresponding wild-type control. Data presented in both graphs are the mean and standard
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This concentration of cadmium was previously shown to dere-
press Hsf1,57 the evolutionarily conserved transcription factor
and master regulator of S. cerevisiae HSR.75 Consistent with
the modest induction of HSE-lacZ by KP1019, Hsf1 was only
weakly implicated in the TFRank analysis of KP1019 response.
Specifically, this transcription factor ranked 30th amongst the
100+ potential regulators reported by Yeastract. To determine
whether the KP1019-dependent induction of chaperones was
likely to be physiologically significant, we pre-treated yeast with
KP1019 and then tested the yeast for heat tolerance. As can be
seen in Fig. 8B, pre-treatment with KP1019 increased yeast
tolerance to heat shock.
In addition to increasing abundance of proteins involved in
protein (re)folding, clusters of ribosomal and ribosomal bio-
genesis proteins exhibited elevated levels (Fig. 3A). Specifically,
the abundance of ribosomal and ribosomal biogenesis proteins
in these intertwined clusters were increased an average of
four-fold (range = 1.6 to 13-fold, not including Utp9, which
was not detected in the absence of KP1019) Consistent with the
visualization depicted in Fig. 3A, STRING’s analytics revealed
statistically significant (FDR = 0.002) enrichment of proteins
associated with the cellular component GO term ‘‘cytosolic
ribosome’’. Likewise Yeastract identified the transcription
factor Sfp1 – a major regulator of ribosomal gene expression85 –
as a potential contributor to KP1019-dependent changes in
protein abundance (Fig. 5A). Notably, the levels of Sfp1 itself
increased four-fold in the drug treated samples.
Since elevated levels of translation machinery correlate with
increased oxaliplatin sensitivity,86 and since KP1019 increases
abundance of several ribosomal proteins (Fig. 3), we hypothesized
that KP1019 might increase oxaliplatin sensitivity. As seen in
Fig. 9A, treating yeast with 80 mg ml1 KP1019 for three hours
resulted in a roughly 60% decrease in the IC50 for oxaliplatin.
To determine whether this effect was synergistic, we examined
a wider range of KP1019 concentrations (Fig. 9B), analysing the
resulting growth inhibition with the zero interaction potency
(ZIP) model, which has a relatively low false positive rate and
avoids the assumptions associated with more traditional addi-
tivity and independence models.87 According to this model a
delta (d) score of zero suggests no interaction between two
drugs, whereas scores greater than zero indicate synergy and
scores below zero correspond to antagonism. Although the
average d of 5.18 suggests only modest synergy between
KP1019 and oxaliplatin, within the larger interaction landscape
there is a region of synergy at moderately high doses of both
drugs, peaking at d = 25 (Fig. 9C).
Discussion
In this study, we used the budding yeast S. cerevisiae as a model
organism to examine the global effects of the promising
anticancer ruthenium complex KP1019 at 80 mg ml1, a concen-
tration used in a prior transcriptomic study in yeast.29 Notably,
this concentration is less than two-fold higher than the
maximum plasma concentration (51.5 mg ml1) observed in a
Phase I clinical trial.20 Using a slightly higher concentration in
S. cerevisiae is appropriate, as yeast often have elevated levels of
resistance to antineoplastic agents.88
Fig. 7 KP1019 activates the DNA damage response. (A) Yeast carrying an
RNR3-lacZ reporter construct were treated with KP1019 for 3 hours prior
to measuring b-galactosidase activity. (B) Yeast were grown overnight in
the indicated concentrations of KP1019 then absorbance at 630 nm was
measured to quantify culture density. Data presented in both panels are
the mean and standard deviation of three trials.
Fig. 8 KP1019 activates the heat shock response. (A) Wild-type yeast
carrying an HSE-lacZ reporter construct were treated with KP1019 or
CdSO4 for 3 hours prior to measuring b-galactosidase activity. Bars and
error bars represent the mean and standard deviation of 3 independent
trials. Brackets and asterisks indicate statistically significant differences
(p o 0.01). (B) Wild-type yeast were pre-treated with the indicated
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Consistent with previous findings, our results demonstrated
that the drug significantly increased levels of proteins involved
in genotoxic, proteotoxic, and oxidative stress responses.
With respect to the drug’s impact on DNA, KP1019 binds
model nucleotides in vitro89 and damages DNA in cancer24 and
yeast27,28 cells; in S. cerevisiae, the resulting activation of the
DNA damage response (DDR) leads to cell cycle arrest.29 Here,
we observed induction of the ribonucleotide reductase complex
(Fig. 3A) in a DDR-dependent manner (Fig. 7), and there was no
evidence to suggest that these or other differences in protein
levels were due solely to the drug’s impact on cell cycle
progression. These new data supporting KP1019-dependent
activation of the DDR confirm prior studies, while validating
our experimental design. We also noted that the drug induced
filamentous growth in yeast (Fig. 5B), which may be a sign of
replication stress.90
Interestingly, DNA damage and repair were not among
the enriched GO terms identified in our bioinformatics ana-
lyses. Some lack of congruence with recent transcriptomic
studies29,32 would be expected due to differences that arise
when characterizing proteomes as opposed to transcriptomes.
For example, osmotic or oxidative insults have been shown to
impact translation, at times resulting in changes to the abun-
dance of specific proteins.91–94 Divergence from transcriptomic
studies may also stem from technical reasons. Although all
three studies treated yeast with KP1019 for three hours prior to
analysis, discrepancies included use of different wild-type yeast
strains and varying concentrations of KP1019 (80 mg ml1 (here
and Bierle et al.29) vs.50 mg ml1 32), and different cut-offs for
bioinformatic analyses (e.g. – 1.5 (here and Golla et al.32) vs.
3.529 fold induction). Solubilizing the drug in DMSO, as in
Golla et al.32 but not here, may also be a confounding variable,
as DMSO impacts KP1019’s stability (Cetto A and Stultz LK,
personal communication). Regardless of the etiology of the
variation between studies, our results support the existence of
drug targets besides DNA. In particular, network and GO term
analyses are consistent with the drug impacting proteins and
redox processes.
In support of drug-dependent oxidative stress, we observed
increased abundance of proteins involved in the pentose phos-
phate pathway and GSH synthesis (Fig. 3 and 6). Though these
results are aligned with the oxidative stress observed in mam-
malian studies,24 increased expression of oxidative stress genes
was not reported in the previous transcriptomic analyses in
yeast.29,32 Regardless, we were able to verify induction of
oxidative stress by measuring drug-dependent increases in
fluorescence of the redox-sensitive dye DCFH-DA (Fig. 6B) and
modest increases in sensitivity of yeast lacking Yap1 (Fig. 6C),
the master regulator of the S. cerevisiae oxidative stress
response.75,77 These findings are consistent with the ‘‘activa-
tion by reduction’’ hypothesis,95 according to which, KP1019 is
a pro-drug that becomes bioactive after its central ruthenium
atom is reduced from Ru3+ to Ru2+. Unlike most platinum-
based drugs, which do not change oxidation states, KP1019 is
more likely to be reduced in the low oxygen microenvironment
of a poorly vascularized solid tumour. This localized activation
may contribute to this ruthenium complex’s selectivity for
malignant tissues.95 An anticipated byproduct of KP1019
reduction would be reactive oxygen species (ROS), which could
help mediate the drug’s toxic effects. Although the more dra-
matic sensitivity of DDR mutants (Fig. 7B) relative to the Yap1
deletion strain (Fig. 6C) suggests DNA damage plays a greater
role in the drug’s toxicity, the physiological significance and
origins of drug-induced ROS require further investigation, as
the oxidative stress and DNA damage responses are highly
intertwined. For example, oxidative stress is a well-known cause
of DNA damage,96 and DNA damage leads to signalling-related
increases in ROS.97,98
In addition to verifying KP1019’s ability to induce DNA damage
and oxidative stress, here we showed significant increases in levels of
proteins involved in protein folding (Fig. 3). In fact, the chaperone
Hsp104 showed the greatest fold increase in abundance following
Fig. 9 KP1019 sensitizes yeast to oxaliplatin. (A) Yeast were pre-treated with or without 80 mg ml1 KP1019 for 3 hours. Then the oxaliplatin IC50 was
determined as described in Fig. 7B. Data presented are the mean and standard deviation of three trials. (B and C) Yeast were pre-treated with the indicated
concentrations of KP1019 for three hours prior to 18–24 hours of growth in the presence of oxaliplatin. Data shown are the dose response matrix (B) and
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drug treatment (Fig. 2). Though analogous findings were not
reported in previous transcriptomic studies,29,32 these observa-
tions are consistent with KP1019’s reported binding to proteins
in the cytosolic fraction of cancer cells.25 The drug’s effects on
proteins may be similar to those of other metals which perturb
protein function by binding to thiols,5,6 displacing native metal
cofactors,99 or causing aggregation.7,100 Additional impacts on
proteins may be related to KP1019’s effect on protein turnover.
For example, our visualization of interactions between proteins
with lowered abundance revealed a small cluster of proteins
involved in the ubiquitin–proteasome system (Fig. 4A). Notably,
deletion of RAD4 and RPT6 have previously been shown to
increase accumulation of ubiquitinated proteins.101,102 Thus
KP1019-dependent reductions in the levels of these proteins
may contribute to the previously observed ability of the drug to
result in global increases in ubiquitination.31
Regardless of the mechanism(s) by which KP1019 impacts
protein folding and turnover, bioinformatics (YeastMine) analysis
implicated the evolutionarily conserved transcription factor Hsf1
as a potential contributor to KP1019-dependent changes in
protein levels. A reporter assay supported this conclusion
(Fig. 8). In yeast and mammalian cells, Hsf1 is repressed by its
interactions with Hsp70 chaperones.73,103 In S. cerevisiae, dere-
pression can occur by misfolded proteins titrating Ssa1 (Hsp70)
away from Hsf175 or by chemicals binding to or oxidizing Ssa1
thiols, thereby removing/displacing chaperones from Hsf1.57
Additional research will be required to determine which of
these mechanisms, if any, applies to KP1019. The importance
of drug-dependent perturbation of protein homeostasis relative
to the drug’s genotoxicity and ROS-inducing capabilities also
remains an open question, as HSF1 is an essential gene in
yeast,104 which precludes analysis of deletion strains.
Beyond alterations to protein (re)folding and turnover, we
observed significant increases in levels of proteins involved in
translation (Fig. 3). Although many stresses have previously been
shown to repress expression of genes involved in ribosomal
structure and biogenesis,105 recent transcriptomic analyses of
KP1019,32 other ruthenium complexes,106,107 and the metal salts
AgNO3, CdCl2, HgCl2, and ZnSO4
2 showed induction of ribosomal
structural and biogenesis genes. Moreover, a re-analysis of pub-
lished transcriptomic data,29 using a 1.5-fold (vs. 3.5-fold) cut-off
for gene induction also revealed an enrichment of ribosomal
genes. Specifically, PANTHER identified ‘‘cytosolic translation’’ as
the biological process GO term with the lowest FDR (0.0002).
Notably, low levels (0.02%) of the DNA damaging agent methyl
methane sulfonate (MMS) have also been shown to induce
expression of ribosomal proteins in yeast.60 Although MMS is
capable of damaging proteins,108–110 a major mode of its action is
DNA damage, raising the possibility that KP1019’s impacts on
ribosomal proteins/genes may be related to its genotoxicity. The
induction of ribosomal proteins following KP101932 and MMS60
treatment has been linked to the transcription factor Sfp1, which
was implicated in our bioinformatics analysis (Fig. 5A). As a
‘‘generalist,’’ Sfp1 responds to diverse stresses, including oxida-
tive and osmotic stress,111 both of which are caused by KP1019
(Fig. 6 and Singh et al.31). However, precisely how KP1019
impacts translation remains unclear. For example, it is not yet
known whether KP1019 affects expression of ribosomal RNAs
and/or whether the drug impacts the pool of mRNAs being
translated (i.e. – the translatome).
Regardless, since elevated levels of translation machinery
correlate with oxaliplatin sensitivity,86 we hypothesized that
KP1019-dependent increases in abundance of ribosomal and
ribosomal biogenesis proteins might sensitize yeast to oxali-
platin. In fact, that was the case (Fig. 9), which is consistent
with models for synergy which predict that agents acting on
similar processes may be more likely to have synergistic (as
opposed to additive or antagonistic) effects.112 Given that both
oxaliplatin and KP1019 impact translation (Fig. 3, ref. 32
and 86) and that ‘‘translation addicted’’ cancer cell lines are
hypersensitive to oxaliplatin,86 future studies might explore
whether these same cell lines are hypersensitive to KP1019. If
so, KP1019’s effects on protein synthesis may explain its
specificity for cancer cells, as many hematological and solid
tumours have elevated levels of translation machinery.113–115
This specificity for translation-addicted cancer cells may, in
turn, contribute to KP1019’s lack of dose-limiting toxicity.
Conclusions
Here we report the first global proteomic analysis of the effects
of KP1019 on eukaryotic cells. Our findings reveal a multi-
faceted response that could be explained by the presence
of both nuclear and non-nuclear targets. Although KP1019’s
ability to damage DNA is well-established in both cancer and
yeast cells.24,27,28 here we provide the first evidence supporting
KP1019-dependent induction of oxidative stress in yeast. This
finding further supports the utility of yeast as a model for
studying KP1019, as this drug has been shown to cause oxidative
stress in colorectal cancer cells.24 The observed increases in
chaperones and translation machinery suggest that proteins
serve as a significant cytosolic target of the drug. These findings
may have long-term clinical implications, as translation has
emerged as a promising target for chemotherapeutics.115,116
Moreover, the ability of KP1019 to sensitize yeast to oxaliplatin
suggests that KP1019 may be a robust component of combi-
nation therapy regimens.
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Efficacy of new ruthenium complexes against chemically
induced autochthonous colorectal carcinoma in rats,
Anticancer Res., 1989, 9, 761–765.
24 S. Kapitza, M. A. Jakupec, M. Uhl and B. K. Keppler, and B.
Marian, The heterocyclic ruthenium(III) complex KP1019
(FFC14A) causes DNA damage and oxidative stress in
colorectal tumor cells, Cancer Lett., 2005, 226, 115–121.
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